I Hate Dialysis Message Board

Dialysis Discussion => Dialysis: Home Dialysis - NxStage Users => Topic started by: M3Riddler on November 05, 2009, 05:47:06 PM

Title: NxStage(R) Reports Third Quarter 2009 Financial Results
Post by: M3Riddler on November 05, 2009, 05:47:06 PM
LAWRENCE, Mass., Nov. 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today posted strong third quarter results. Net revenue for the third quarter of 2009 was $38.0 million, compared with the Company's guidance for third quarter revenue in the range of $32.5 to $34.5 million. The Company's third quarter revenue includes approximately $2.5 million of third quarter sales within the In-Center market that management had previously expected to be deferred to the fourth quarter of 2009. The Company further exceeded its guidance as a result of stronger than anticipated machine and disposable sale...

View Article Feed..  (http://www.nxstage.com/ir.cfm?c=142059&p=RssLanding&cat=news&id=1351553)

///M3R
Title: Re: NxStage(R) Reports Third Quarter 2009 Financial Results
Post by: Rerun on November 05, 2009, 06:36:29 PM
So they cleared 38M??  Or is that before expenses..........

If they cleared 38M then they are charging the tax payers too much!  Is there any common sense as to how much money is enough.??
Title: Re: NxStage(R) Reports Third Quarter 2009 Financial Results
Post by: Wallyz on November 06, 2009, 01:50:33 PM
Quote
quarter of 2008.
Net loss for the third quarter of 2009 was $10.0 million, or ($0.22) per share. This compares to a net loss of $15.0 million, or ($0.33) per share for the third quarter of 2008, which included the negative impact of a $1.8 million change in fair value of financial instruments.
Cash and cash equivalents as of September 30, 2009 were $22.1 million. The Company's cash usage for the third quarter of 2009 was $2.4 million.
For the third quarter of 2009, the Company had an Adjusted EBITDA loss of $2.4 million, adjusted for stock-based compensation, deferred revenue recognized and other non-recurring expenses, compared with an Adjusted EBITDA loss of $7.3 million in the third quarter of 2008. These results were better than the Company's guidance for an Adjusted EBITDA loss of $3.0 to $4.0 million for the third quarter of 2009. (See the exhibits for a reconciliation of this non-GAAP measure.)

Nx Stage is still losing money. I think the corporate plan is negative income until 2011.  If they can't pull it out in 2011, those of us at home may be screwed.